HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities.

AuthorsTessa Bystrup Boyles, Mette Schødt, Helle Westergren Hendel, Anders Krarup-Hansen, Niels Junker
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 59 Issue 7 Pg. 793-796 (Jul 2020) ISSN: 1651-226X [Electronic] England
PMID32285728 (Publication Type: Letter)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab
Topics
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
  • Antineoplastic Agents, Immunological (adverse effects, therapeutic use)
  • Carcinoma, Merkel Cell (drug therapy)
  • Comorbidity
  • Female
  • Humans
  • Male
  • Skin Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: